GibbWRGLessAJ: The relevance of Lewy Body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry51: 745–752, 1988.
2.
GelbDJOlivierEGilmanS: Diagnostic criteria for Parkinson's disease. Arch Neurol56: 33–39, 1999.
3.
HughesAJDanielSE: The accuracy of the clinical diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain125: 861–870, 2002.
4.
AgidYAhlskogE: Levodopa in the treatment of Parkinson's disease: A consensus meeting. Mov Disord14: 911–913, 1999.
5.
BrooksDJ: Neuroimaging in movement disorders. In: WattsRLKoellerWC, (eds) Movement Disorders: Neurologic Principles and Practice. McGraw-Hill, New York: 31–48, 1997.
6.
HalldinCGulyasB: Brain radioligands: State of the art and new trends. Q J Nucl Med Jun45 (2): 139–152, 2001.
7.
BooijJHemelaarJTGM: One-day protocol for imaging on the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I] FPCIT SPECT. J Nucl Med40: 753–761, 1999.
8.
MarekKLSeibylJP: [123I] beta - CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology46: 231–237, 1996.
9.
BenamerHTSPattersonJGrossetDG: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord15: 503–510, 2000.
10.
BoojiJTissingG: [I-123] FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's diseaseJ Neurol Neurosurg Psychiatry62: 133–140, 1997.
11.
BerendseHWBooijJ: Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patient's relatives with a decreased sense of smell. Ann Neurol50: 34–31, 2001.
12.
MarekKInnisR: [123I] beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology57: 2089–2094, 2001.
13.
AntoniniAColomboGL: Il ruolo della SPECT in associazione a Ioflupane nella diagnosi della Malattia di Parkinson. Farmacoeconomia e percorsi terapeutici3: 125–132, 2002.
